232 related articles for article (PubMed ID: 19588501)
1. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
[TBL] [Abstract][Full Text] [Related]
2. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
3. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Lim SJ; Roh JK; Noh SH; Chung HC
Anticancer Drugs; 2011 Sep; 22(8):801-10. PubMed ID: 21572321
[TBL] [Abstract][Full Text] [Related]
4. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Ichikawa W; Takahashi T; Suto K; Shirota Y; Nihei Z; Shimizu M; Sasaki Y; Hirayama R
Int J Cancer; 2006 Oct; 119(8):1927-33. PubMed ID: 16736497
[TBL] [Abstract][Full Text] [Related]
5. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
6. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Choi IS; Lee HS; Lee KW; Kim H; Kim KH; Kim YJ; Kim JH; Kim WH; Lee JS
Med Oncol; 2011 Dec; 28(4):991-8. PubMed ID: 20533001
[TBL] [Abstract][Full Text] [Related]
8. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
9. High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis.
Wang D; Yu X; Wang X
Int J Biol Markers; 2016 May; 31(2):e101-9. PubMed ID: 27012156
[TBL] [Abstract][Full Text] [Related]
10. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
[TBL] [Abstract][Full Text] [Related]
11. A predictive factor for the response to S-1 plus cisplatin in gastric cancer.
Miyazaki I; Kawai T; Harada Y; Moriyasu F
World J Gastroenterol; 2010 Sep; 16(36):4575-82. PubMed ID: 20857529
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
17. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Sasako M; Terashima M; Ichikawa W; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H
Gastric Cancer; 2015 Jul; 18(3):538-48. PubMed ID: 25112781
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
Nakayama I; Chin K; Matsushima T; Takahari D; Ogura M; Shinozaki E; Suenaga M; Ozaka M; Wakatsuki T; Ichimura T; Hiroki O; Yamaguchi K
Int J Clin Oncol; 2017 Dec; 22(6):1060-1068. PubMed ID: 28748355
[TBL] [Abstract][Full Text] [Related]
20. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]